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Background: Socioeconomic inequalities impact on the survival of head and neck
cancer (HNC) patients, but there is limited understanding of the explanations of the
inequality, particularly in long-term survival.
Methods: Patients were recruited from the Scottish Audit of Head and Neck Cancer
between 1999 and 2001 and were linked to mortality data as at 30th September 2013.
Socioeconomic status was determined using the area-based Carstairs 2001 index.
Overall and disease-specific survival were calculated using the Kaplan-Meier method
with 95% confidence intervals (CI’s) at 1-, 5-, and 12-years. Net survival at 1-, 5-, and
12-years was also computed with 95% CIs. Cox proportional hazard models with 95%
CIs were used to determine the explanations for the inequality in survival by all-cause
mortality and disease-specific mortality with 95% CIs.
Results: Most patients were from the most deprived group, and were more likely to
smoke, drink, have cancer of a higher stage and have a lower WHO Performance Status.
A clear gradient across Carstairs fifths for unadjusted overall and disease-specific survival
was observed at 1-, 5-, and 12-years for patients with HNC. Following the adjustment for
multiple patient, tumor and treatment factors, the inequality in survival for patients with
HNC had attenuated and was no longer statistically significant at 1-, 5-, and 12-years.
Conclusion: A clear gradient across Carstairs fifths for unadjusted overall,
disease-specific and net survival was observed at 1-, 5-, and 12-years for HNC patients in
Scotland from 1999 to 2001. This study concludes that explanations for the inequality in
the survival of patients with HNC are not straightforward, and that many factors including
various patient, tumor and treatment factors play a part in the inequality in the survival of
patients with HNC.
Keywords: head and neck cancer, socioeconomic status, survival, epidemiology, cohort, scotland, long term
survival, deprivation
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INTRODUCTION
Cancer survival often favors those who are from
socioeconomically advantaged areas or have a more aﬄuent
backgrounds (1), and explanations for these socioeconomic
inequalities are complex and difficult to explain. In the 1997
landmark IARC publication Social Inequalities in Cancer,
Auvinen (2) assessed the socioeconomic factors that are
associated with cancer survival, and identified research gaps
in understanding the determinants of survival beyond cancer
stage. Auvinen concluded that there was “urgent need” to
understand the drivers of the inequality in cancer survival,
and more than 20 years later, the evidence-base is not much
further forward. Woods et al. (3) carried out a comprehensive
review to determine the origins of socioeconomic inequalities in
all-cancer survival and concluded that stage at diagnosis, access
to health services, and comorbidity may explain some of the
association.
Previous analyses of the Scottish Audit of Head and Neck
Cancer (SAHNC) cohort have presented 5-year overall survival
and 5-year disease-specific survival (4–7). In 2010, Robertson
et al. (7) reported the impact of socioeconomic status (SES)
on survival at 5-years and outlined that socioeconomic status
was no longer an independent predictor of survival following
the adjustment of multiple covariates. To add to this previous
research, the aims of this study are to assess socioeconomic
inequality in the survival of head and neck cancer patients
assessing short-, mid-, and long-term survival, and to provide an
understanding of the explanation of the inequality in the survival
of these patients via different measurements of survival including
overall, disease-specific and net survival estimates.
MATERIALS AND METHODS
Patients
The SAHNC cohort recruited patients between 1st September
1999 and 31st August 2001—the methods have previously been
described (4–7). Data were recorded on new HNC patients
diagnosed in Scotland during this 2 year period. Quality
assurance processes were carried out including cross-checking
the data with medical and pathology results.
Data Linkage and Approvals
The SAHNC cohort was linked to the National Records of
Scotland (NRS) mortality data as at 30th September 2013
by ISD Scotland. Records were linked using an established
probability matching technique based on the Howard Newcombe
principle (8) which matches individual patients to their
national Community Health Index (CHI) number—the unique
healthcare identifier that is used in the National Health Service
(NHS) in Scotland. Data were linked to mortality forms
which outlined the primary and secondary causes of death
using ICD10 codes. Information governance and data linkage
approvals were obtained from the NHS Privacy Advisory
Committee (now known as the Public Benefits and Privacy
Panel).
Measurement of Socioeconomic Status
SES was determined using the area-based Carstairs 2001 index
(9, 10) which is defined from 2001 Census data consisting of
four variables including proportion of unemployed males, those
in social classes IV and V, those who do not own a car, and a
measurement for overcrowding defined as a density of more than
one person per room per private household. The Carstairs index
is split at a population level by creating equal fifths using the
quintile cut offs—group 1 represents the most aﬄuent patients
and group 5 represents the most deprived patients.
Variables Used for Adjustment
Patient factors (age at diagnosis, sex, smoking behavior,
alcohol consumption and patient performance status), tumor
factors (stage and anatomical site) and treatment factors
(treatment modality and geographic location of treatment)
were collected at baseline and no further data was collected
afterwards. Smoking behavior and alcohol consumption were
determined from questionnaires at the time of diagnosis which
allowed the following “tick-box” options for patient selection:
“current smoker,” “previous smoker” and “never smoked,”
and “current problem drinker,” “previous problem drinker” or
“occasionally/never drinks”—no further data were collected on
the patients’ habits following diagnosis. Patient performance
status was classified at diagnosis using the World Health
Organization (WHO) Performance Status (11), which groups
patients into one of five categories based on their level of physical
abilities (“normal activity,” “strenuous activity restricted,” “up
and about for more than 50% of waking hours,” “confined
to a bed or chair for more than 50% of waking hours,” and
“confined to a bed or chair for 100% of waking hours”). Tumor
stage was determined using the Tumor, Node and Metastases
(TNM) Classification of Malignant Tumors (12), and the cohort
was grouped into stage I, II, III, or IV. Anatomical site was
classified using the International Classification of Disease version
10 (13), grouped into seven categories—lip (C00.9), larynx (C32),
nasal cavity (C11.9, C30.0, C31), oral cavity (C02–C04, C05.0,
C06, C14), oropharynx (C01, C05.1–, C09, C10), hypopharynx
(C12, C13), and other or salivary gland (C07, C08, C30.1,
C41, C44, C76, C77). Treatment modality was grouped into
five categories: (i) surgery only; (ii) radiotherapy only; (iii)
surgery combined with radiotherapy; (iv) chemotherapy only,
chemotherapy combined with surgery, chemotherapy combined
with radiotherapy, and chemotherapy combined with both
surgery and radiotherapy; and (v) no treatment. Location of
treatment was based on the service delivered in the Scottish
Cancer Networks located in three geographic region—West of
Scotland Network (WoSCAN) (which comprises health board
areas of Ayrshire and Arran, Forth Valley, Greater Glasgow,
Clyde and Lanarkshire); South East Scotland Cancer Network
(SCAN) (Borders, Dumfries and Galloway, Fife, Lothian); and
North of Scotland Cancer Network (NOSCAN) (Grampian,
Highland, Orkney, Shetland, Tayside, Western Isles).
Statistical Methods
Overall and disease-specific survival were calculated using the
Kaplan-Meier method with 95% confidence intervals (CI’s).
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Overall survival considered all causes of death, whereas disease-
specific survival only considered deaths where the patients’
primary cause of death on their death certificate was a HNC
ICD10 code. Cox proportional hazard models with 95% CIs
were used to determine the explanations for the inequality in
survival for all-cause mortality and disease-specific mortality
with 95% CIs. Overall survival, disease-specific survival, and Cox
proportional hazards models for all-cause mortality and disease-
specific mortality were calculated using SAS Software, version
9.4 (SAS Institute Inc., USA). Net survival with 95% CIs was
calculated by the Pohar-Perme method (14, 15) using the stns
command in Stata 14 (16, 17), and using life-tables provided by
the Cancer Survival Group at the London School of Tropical
Hygiene and Medicine (18) These life-tables were standardized
by age, sex, and Carstairs 2001 quintile. The Slope Index of
Inequality (SII) was calculated based on the regression of the
mid-point of survival for mortality for each SES group in each
model (19).
RESULTS
Cohort Recruitment
The SAHNC cohort recruited 77% (n = 1,910) of HNC cases
that were diagnosed and recorded in the Scottish Cancer Registry
over the study period from 1st September 1999 to 31st August
2001. Of the 1,910 patients in the baseline cohort, 1,895 were
linked to 12-year mortality records−15 patients were excluded
as they were unable to be matched to CHI numbers for data
linkage follow-up. A further 15 patients were excluded as they
could not be matched to Carstairs 2001 fifths, and 60 patients
over the age of 85 were also excluded, which was a requirement
for the successful computation of net survival for 12-year
follow-up. A remaining 1,820 patients were included in the
analyses.
Patient Demographics by SES Carstairs
2001 Fifths
Table 1 outlines the demographic characteristics broken down
by Carstairs 2001 fifths of the 1,820 patients. Most patients
were from the most deprived regions of Scotland (29.0%),
whereas only 13.2% of patients were from the most aﬄuent
areas of Scotland. There were no differences in the distribution
of patients in each age category or between males and females
across the Carstairs 2001 fifths. As deprivation increased from
group 1 (most aﬄuent) to group 5 (most deprived), the
proportion of current smokers in each group also increased,
and similarly, the proportion of patients with current alcohol
problems increased. The number of patients experiencing normal
WHO activity decreased across the SES groups, and the most
deprived patients had the greatest proportion of Stage IV cancers
(40.0%) compared to other groups. There was a slight difference
in the treatment modalities used between groups, and the most
deprived group had the smallest proportion of patients treated
with curative intent. There were no clear trends by Carstairs 2001
fifths for anatomical site, Scottish Cancer Networks, or type of
primary cause of death.
Overall, Disease-Specific, and Net Survival
One-, five-, and twelve-year overall, disease-specific and net
survival by Carstairs 2001 fifths are displayed in Table 2. The
Slope Index of Inequality (SII) for all three methods of survival
and at each time point are also displayed in Table 2. One-year
overall survival for the most deprived patients was 71.8% (67.7%,
75.4%), whereas the most aﬄuent patients’ was higher at 83.4%
(78.1%, 87.5%). By 5-years, the inequality remained the same,
and by 12-years the difference in overall survival had reduced,
which can be demonstrated by a similar SII at 5-year [SII = 12.9
(−1.8, 27.5)] and a reduced SII at 12-years [SII= 7.4 (−2.7, 17.5)]
compared to the SII at 1-year 12.7 (6.7, 18.8). One-year disease-
specific survival for the most deprived patients was 79.1% (75.2%,
82.4%) whereas the most aﬄuent patients’ was higher at 88.8%
(83.9%, 92.2%). By 5- and 12-years, the gap between the most
aﬄuent and most deprived patients for disease-specific survival
had widened, and the SII had increased from 9.5 (1.4, 17.7) at
1-year to 12.5 (−1.8, 26.9) and 16.5 (1.5, 31.5) at 5- and 12-
years, respectively. Net survival at 1 year for the most deprived
patients was 73.7% (69.7%, 77.6%), compared to themost aﬄuent
patients at 86.1% (81.3%, 91.0%). The inequality between the
net survival results for the most deprived patients and the most
aﬄuent patients was strong at 1-year with SII of 13.6 (7.1, 20.1),
however this had widened by 5-years with SII of 16.1 (−1.0, 33.3),
and by 12-years a weak inequality remained with the SII at 6.6
(−17.2, 30.3).
Cox Models for All-Cause Mortality
Minimally adjusted and fully adjusted Cox Proportional Hazards
models for all-cause mortality are displayed in Table 3. Clear
trends can be observed following minimal adjustment by age and
sex in the models for all-cause mortality at all three time points,
and there is statistical evidence to confirm an inequality in all-
cause mortality at 1- (p < 0.001), 5- (p < 0.001), and 12-years (p
< 0.001). At 1 year, the most deprived patients were 46% more at
risk when the model was adjusted by age, sex and patient factors
[HR 1.46, (1.02, 2.09)], and there was evidence of a difference
between the most aﬄuent patients and those who were in the
most deprived group (p = 0.037). Following the adjustment for
age, sex, tumor and treatment factors, there was no longer any
evidence of a difference between the most aﬄuent patients and
the patients in other Carstairs 2001 fifth (p = 0.113), and this
result was also clear when the model was fully adjusted by age,
sex, patient, tumor and treatment factors (p = 0.351). This was
also demonstrated by the SII’s which had reduced from 1.1 (0.7,
1.5) in the minimally adjusted model by age and sex, to 0.2 (−0.4,
0.7) in the fully adjusted model. By 5- and 12-years, the gaps
between the risk of all-cause mortality for the most aﬄuent and
themost deprived patients had narrowed in all models, which can
be demonstrated by a reduction in all the models’ SIIs between
1-, 5-, and 12-year follow-up—for example, in the model that
was minimally adjusted by age and sex, the SII had reduced from
1.1 (0.7, 1.5) at 1-year, to 0.6 (0.1, 1.0) at 5-years, and 0.4 (0.1,
0.7) at 12-years, whereas in the fully adjusted model the SII had
reduced from 0.2 (−0.4, 0.7) at 1-year, to 0.03 (−0.6, 0.6) at 5-
years, and −0.1 (−0.5, 0.4) at 12-years. There was no longer
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TABLE 1 | Patient demographic, behavioral, tumor, and treatment characteristics by Carstairs quintiles.
Variable Total (Col. %) Frequencies of Carstairs 2001 quintiles (Col. %) Chi-square
p-value
1—Most affluent 2 3 4 5—Most deprived
Whole cohort (Row %) 1,820 (100.0%) 241 (13.2%) 317 (17.4%) 325 (17.9%) 409 (22.5%) 528 (29.0%) –
Age at diagnosis 0.470
Less than 45 99 (5.4%) 16 (6.6%) 23 (7.3%) 16 (4.9%) 21 (5.1%) 23 (4.4%)
45 to 54 288 (15.8%) 35 (14.5%) 44 (13.9%) 45 (13.9%) 68 (16.6%) 96 (18.2%)
55 to 64 592 (32.5%) 70 (29.1%) 105 (33.1%) 108 (33.2%) 140 (34.2%) 169 (32.0%)
65 to 74 551 (30.3%) 72 (29.9%) 90 (28.4%) 111 (34.2%) 108 (26.4%) 170 (32.2%)
75 and over 290 (15.9%) 48 (19.9%) 55 (17.4%) 45 (13.9%) 72 (17.6%) 70 (13.3%)
Sex 0.440
Male 1,300 (71.4%) 161 (66.8%) 227 (71.6%) 236 (72.6%) 289 (70.7%) 387 (73.3%)
Female 520 (28.6%) 80 (33.2%) 90 (28.4%) 89 (27.4%) 120 (29.3%) 141 (26.7%)
Smoking status <0.001
Current smoker 1,134 (62.3%) 118 (49.0%) 173 (54.6%) 191 (58.8%) 256 (62.6%) 396 (75.0%)
Previous smoker 405 (22.3%) 60 (24.9%) 86 (27.1%) 68 (20.9%) 100 (24.5%) 91 (17.2%)
Never smoked 221 (12.1%) 56 (23.2%) 45 (14.2%) 50 (15.4%) 41 (10.0%) 29 (5.5%)
Not recorded 60 (3.3%) 7 (2.9%) 13 (4.1%) 16 (4.9%) 12 (2.9%) 12 (2.3%)
Alcohol consumption <0.001
Current (problem) drinker 496 (27.3%) 51 (21.2%) 77 (24.3%) 80 (24.6%) 108 (26.4%) 180 (34.1%)
Previous (problem) drinker 212 (11.7%) 25 (10.4%) 29 (9.2%) 49 (15.1%) 47 (11.5%) 62 (11.7%)
Occasional/never drank 891 (49.0%) 138 (57.3%) 164 (51.7%) 150 (46.2%) 198 (48.4%) 241 (45.6%)
Not recorded 221 (12.1%) 27 (11.2%) 47 (14.8%) 46 (14.2%) 56 (13.7%) 45 (8.5%)
WHO performance status 0.003
Normal activity 825 (45.3%) 137 (56.9%) 169 (53.3%) 137 (42.3%) 177 (43.3%) 205 (38.8%)
Strenuous activity restricted 465 (25.6%) 54 (22.4%) 66 (20.8%) 94 (28.9%) 102 (24.9%) 149 (28.2%)
Up and about >50% 137 (7.5%) 18 (7.5%) 23 (7.3%) 17 (5.2%) 33 (8.1%) 46 (8.7%)
Confined to bed/chair >50% 97 (5.3%) 8 (3.3%) 18 (5.7%) 22 (6.8%) 26 (6.4%) 23 (4.4%)
Not recorded 296 (16.3%) 24 (10.0%) 41 (12.9%) 55 (16.9%) 71 (17.4%) 105 (19.9%)
Anatomical site 0.470
Lip 85 (4.7%) 11 (4.6%) 17 (5.4%) 18 (5.5%) 23 (5.6%) 16 (3.0%)
Larynx 584 (32.1%) 71 (29.5%) 102 (32.2%) 103 (31.7%) 143 (35.0%) 165 (31.3%)
Nasal cavity 85 (4.7%) 12 (5.0%) 14 (4.4%) 22 (6.8%) 15 (3.7%) 22 (4.2%)
Oral cavity 506 (27.8%) 76 (31.5%) 93 (29.3%) 78 (24.0%) 97 (23.7%) 162 (30.7%)
Oropharynx 323 (17.8%) 40 (16.6%) 53 (16.7%) 63 (19.4%) 69 (16.9%) 98 (18.6%)
Hypopharynx 119 (6.5%) 12 (5.0%) 19 (6.0%) 20 (6.2%) 35 (8.6%) 33 (6.3%)
Other/salivary gland 118 (6.5%) 19 (7.9%) 19 (6.0%) 21 (6.5%) 27 (6.6%) 32 (6.1%)
Stage 0.023
I 383 (21.0%) 58 (24.1%) 85 (26.8%) 75 (23.1%) 73 (17.9%) 92 (17.4%)
II 369 (20.3%) 48 (19.9%) 62 (19.6%) 65 (20.0%) 88 (21.5%) 106 (20.1%)
III 273 (15.0%) 37 (15.4%) 42 (13.3%) 40 (12.3%) 80 (19.6%) 74 (14.0%)
IV 662 (36.4%) 79 (32.8%) 102 (32.2%) 125 (38.5%) 145 (35.5%) 211 (40.0%)
Unknown 133 (7.3%) 19 (7.9%) 26 (8.2%) 20 (6.2%) 23 (5.6%) 45 (8.5%)
Treatment modality 0.064
Surgery only 477 (26.2%) 72 (29.9%) 83 (26.2%) 86 (26.5%) 106 (25.9%) 130 (24.6%)
Radiotherapy only 507 (27.9%) 74 (30.7%) 99 (31.2%) 98 (30.2%) 117 (28.6%) 119 (22.5%)
Surgery + radiotherapy 458 (25.2%) 59 (24.5%) 82 (25.9%) 73 (22.5%) 101 (24.7%) 143 (27.1%)
Chemo ± radio ± surgery 249 (13.7%) 23 (9.5%) 34 (10.7%) 48 (14.8%) 56 (13.7%) 88 (16.7%)
No treatment 129 (7.1%) 13 (5.4%) 19 (6.0%) 20 (6.2%) 29 (7.1%) 48 (9.1%)
Network <0.001
WoSCAN (West Scotland) 1,001 (55.0%) 85 (35.3%) 110 (34.7%) 149 (45.9%) 244 (59.7%) 413 (78.2%)
(Continued)
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TABLE 1 | Continued
Variable Total (Col. %) Frequencies of Carstairs 2001 quintiles (Col. %) Chi-square
p-value
1—Most affluent 2 3 4 5—Most deprived
SCAN (East Scotland) 440 (24.2%) 83 (34.4%) 85 (26.8%) 108 (33.2%) 108 (26.4%) 56 (10.6%)
NOSCAN (North Scotland) 379 (20.8%) 73 (30.3%) 122 (38.5%) 68 (20.9%) 68 (20.9%) 59 (11.2%)
Treatment intent 0.053
Curative 1,355 (74.5%) 196 (81.3%) 250 (78.9%) 239 (73.5%) 307 (75.1%) 363 (68.8%)
Palliative 307 (16.9%) 29 (12.0%) 42 (13.3%) 61 (18.7%) 69 (16.9%) 106 (20.1%)
unknown 158 (8.7%) 16 (6.6%) 25 (7.9%) 25 (7.7%) 33 (8.1%) 59 (11.2%)
Primary cause of death 0.063
Cancer—Head and neck 677 (37.2%) 78 (32.4%) 99 (31.2%) 127 (39.1%) 157 (38.4%) 216 (21.6%)
Cancer—Other 308 (16.9%) 46 (19.1%) 54 (17.0%) 61 (18.8%) 73 (17.8%) 74 (14.0%)
Other/unknown 399 (21.9%) 59 (24.5%) 73 (23.0%) 59 (18.5%) 81 (19.8%) 126 (23.9%)
Alive 436 (24.0%) 58 (24.1%) 91 (28.7%) 77 (23.7%) 98 (24.0%) 112 (21.2%)
TABLE 2 | Overall and disease-specific survival at One-, five-, and twelve-years by Carstairs 2001 quintiles for all patients.
1-year p-value 5-years p-value 12-years p-value
OVERALL SURVIVAL
Whole cohort 76.0 (74.0, 77.9) – 46.1 (43.8, 48.4) – 26.3 (24.3, 28.3) –
Carstairs quintile 0.007 0.002 0.010
1 (Most affluent) 83.4 (78.1, 87.5) 49.8 (43.3, 55.9) 27.0 (21.5, 32.7)
2 78.6 (73.6, 82.7) 52.1 (46.4, 57.4) 30.6 (25.6, 35.7)
3 76.3 (71.3, 80.6) 44.6 (39.2, 49.9) 26.2 (21.5, 31.0)
4 75.1 (70.6, 79.0) 47.7 (42.8, 52.4) 26.9 (22.7, 31.3)
5 (Most deprived) 71.8 (67.7, 75.4) 40.5 (36.3, 44.7) 22.9 (19.4, 26.6)
Slope Index of Inequality (95% CIs) 12.7 (6.7, 18.8) 12.9 (−1.8, 27.5) 7.4 (−2.7, 17.5)
DISEASE-SPECIFIC SURVIVAL
Whole cohort 82.3 (80.4, 84.0) – 64.1 (61.7, 66.4) – 56.9 (54.3, 59.4) –
Carstairs quintile 0.031 0.009 0.003
1 (Most affluent) 88.8 (83.9, 92.2) 69.6 (62.9, 75.3) 61.8 (54.4, 68.4)
2 83.2 (78.5, 86.9) 69.8 (64.2, 74.8) 65.6 (59.6, 70.9)
3 82.2 (77.5, 86.1) 61.0 (55.1, 66.4) 55.5 (49.2, 61.3)
4 81.8 (77.5, 85.3) 64.4 (59.2, 69.1) 55.5 (49.9, 60.8)
5 (Most deprived) 79.1 (75.2, 82.4) 59.6 (54.9, 63.9) 51.1 (46.0, 55.9)
Slope Index of Inequality (95% CIs) 9.5 (1.4, 17.7) 12.5 (−1.8, 26.9) 16.5 (1.5, 31.5)
NET SURVIVAL
Whole cohort 78.3 (76.2, 80.3) – 53.9 (51.1, 56.6) – 41.4 (37.7, 45.1) –
Carstairs quintile N/A* N/A* N/A*
1 (Most affluent) 86.1 (81.3, 91.0) 58.1 (50.4, 65.8) 40.4 (30.7, 50.0)
2 80.9 (76.2, 85.5) 61.0 (54.4, 67.6) 43.8 (35.0, 52.6)
3 78.6 (73.8, 83.3) 52.9 (46.4, 59.3) 40.7 (31.5, 49.9)
4 77.2 (72.8, 81.5) 55.8 (50.1, 61.6) 46.6 (38.4, 54.7)
5 (Most deprived) 73.7 (69.7, 77.6) 46.6 (41.7, 51.5) 35.7 (29.6, 41.8)
Slope Index of Inequality (95% CIs) 13.6 (7.1, 20.1) 16.1 (−1.0, 33.3) 6.6 (−17.2, 30.3)
*Trend test does not exist for Net survival.
any evidence of an inequality by all-cause mortality by 5- or 12-
years following the adjustment for age, sex and patient, tumor or
treatment factors.
Cox Models for Disease-Specific Mortality
Minimally adjusted and fully adjusted Cox Proportional Hazards
models for disease-specific mortality are displayed in Table 3.
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TABLE 3 | One-, five-, and twelve-year all-cause mortality (ACM) and disease-specific mortality (DSM) hazard ratios by Carstairs 2001 quintile for all patients with slope
index of inequality (SII) for each measurement and time point.
Variable Adjusted by age and sex Adjusted by patient
factors*
Adjusted by tumor and
treatment factors∧
Adjusted by patient,
tumor and treatment
factors+
HR (95% CIs) p-value HR (95% CIs) p-value HR (95% CIs) p-value HR (95% CIs) p-value
1-year ACM <0.001 0.037 0.113 0.351
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 1.35 (0.92, 2.00) 1.20 (0.81, 1.78) 1.09 (0.74, 1.62) 0.99 (0.67, 1.47)
3 1.53 (1.05, 2.25) 1.31 (0.89, 1.92) 1.42 (0.96, 2.09) 1.28 (0.86, 1.89)
4 1.62 (1.12, 2.33) 1.30 (0.90, 1.89) 1.29 (0.89, 1.88) 1.16 (0.79, 1.69)
5 (Most deprived) 1.96 (1.38, 2.77) 1.46 (1.02, 2.09) 1.32 (0.92, 1.91) 1.16 (0.80, 1.68)
SII (95% CIs) 1.1 (0.7, 1.5) 0.5 (0.2, 0.8) 0.3 (−0.3, 1.0) 0.2 (−0.4, 0.7)
5-year ACM <0.001 0.157 0.065 0.715
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 0.99 (0.78, 1.26) 0.89 (0.70, 1.13) 0.91 (0.72, 1.16) 0.80 (0.63, 1.02)
3 1.22 (0.97, 1.54) 1.07 (0.85, 1.35) 1.29 (1.02, 1.63) 1.11 (0.88, 1.41)
4 1.14 (0.91, 1.43) 0.95 (0.76, 1.19) 1.07 (0.85, 1.34) 0.90 (0.72, 1.14)
5 (Most deprived) 1.43 (1.15, 1.76) 1.11 (0.89, 1.38) 1.17 (0.94, 1.46) 0.97 (0.78, 1.22)
SII (95% CIs) 0.6 (0.1, 1.0) 0.2 (−0.2, 0.6) 0.2 (−0.5, 0.9) 0.03 (−0.6, 0.6)
12-year ACM <0.001 0.624 0.197 0.465
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 0.94 (0.77, 1.15) 0.86 (0.70, 1.04) 0.87 (0.71, 1.06) 0.79 (0.64, 0.96)
3 1.09 (0.89, 1.32) 0.95 (0.78, 1.16) 1.14 (0.94, 1.39) 0.99 (0.81, 1.21)
4 1.08 (0.89, 1.30) 0.89 (0.74, 1.08) 1.02 (0.84, 1.23) 0.86 (0.71, 1.05)
5 (Most deprived) 1.27 (1.06, 1.52) 0.99 (0.82, 1.19) 1.06 (0.88, 1.27) 0.87 (0.72, 1.05)
SII (95% CIs) 0.4 (0.1, 0.7) 0.1 (−0.3, 0.4) 0.1 (−0.4, 0.6) −0.1 (−0.5, 0.4)
1-year DSM 0.001 0.162 0.129 0.431
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 1.59 (0.99, 2.54) 1.41 (0.88, 2.27) 1.23 (0.76, 1.97) 1.11 (0.69, 1.80)
3 1.69 (1.06, 2.69) 1.42 (0.88, 2.27) 1.57 (0.98, 2.52) 1.40 (0.87, 2.26)
4 1.72 (1.10, 2.69) 1.37 (0.87, 2.16) 1.42 (0.90, 2.25) 1.24 (0.78, 1.98)
5 (Most deprived) 2.09 (1.36, 3.22) 1.51 (0.97, 2.34) 1.45 (0.92, 2.29) 1.23 (0.78, 1.96)
SII (95% CIs) 1.1 (0.2, 1.9) 0.7 (−0.1, 3.5) 0.4 (−0.4, 1.3) 0.2 (−0.5, 0.9)
5-year DSM <0.001 0.117 0.046 0.343
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 1.06 (0.77, 1.46) 0.96 (0.70, 1.33) 0.94 (0.68, 1.29) 0.82 (0.59, 1.14)
3 1.41 (1.04, 1.92) 1.24 (0.91, 1.68) 1.49 (1.10, 2.03) 1.29 (0.95, 1.77)
4 1.28 (0.95, 1.72) 1.07 (0.79, 1.45) 1.21 (0.89, 1.63) 1.03 (0.75, 1.40)
5 (Most deprived) 1.55 (1.17, 2.06) 1.21 (0.91, 1.62) 1.27 (0.95, 1.71) 1.07 (0.79, 1.45)
SII (95% CIs) 0.7 (0.1, 1.2) 0.3 (−0.3, 0.8) 0.3 (−0.7, 1.4) 0.1 (−0.7, 1.0)
12-year DSM <0.001 0.066 0.036 0.359
1 (Most affluent) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 0.98 (0.73, 1.33) 0.89 (0.66, 1.20) 0.88 (0.65, 1.19) 0.78 (0.58, 1.06)
3 1.32 (0.99, 1.75) 1.16 (0.87, 1.54) 1.38 (1.04, 1.85) 1.20 (0.90, 1.61)
4 1.27 (0.97, 1.68) 1.06 (0.80, 1.40) 1.19 (0.90, 1.58) 1.02 (0.77, 1.35)
5 (Most deprived) 1.51 (1.16, 1.96) 1.18 (0.90, 1.55) 1.22 (0.92, 1.60) 1.02 (0.77, 1.35)
SII (95% CIs) 0.7 (0.2, 1.2) 0.3 (−0.2, 0.7) 0.3 (−0.6, 1.2) 0.1 (−0.7, 0.9)
*Adjusted by age, sex, and patient factors including smoking status, alcohol consumption and WHO Performance Status. ∧Adjusted by age, sex, tumor and treatment factors including
stage, anatomical site, treatment modality and network of treatment +Adjusted by all factors including smoking status, alcohol consumption, WHO Performance status, stage, anatomical
site, treatment modality and network of treatment.
Similar to the models for all-cause mortality, there were clear
trends following minimal adjustment by age and sex in the
models for disease-specific mortality at all three time points,
and there is statistical evidence to confirm an inequality in
disease-specific mortality at 1- (p = 0.001), 5- (p < 0.001), and
12-years (p < 0.001). Following full adjustment for all factors
including age, sex, patient, tumor and treatment factors, there
was no evidence to support an inequality in excess risk of
Frontiers in Oncology | www.frontiersin.org 6 January 2019 | Volume 8 | Article 673
Ingarfield et al. Inequality in Head and Neck Cancer Survival
disease-specific mortality after 1-year (p= 0.431), which can also
be demonstrated by the SII which had reduced from 1.1 (0.2, 1.9)
in the model minimally adjusted by age and sex, to 0.2 (−0.5, 0.9)
in the fully adjusted model. By 5- and 12-years, the gaps between
the risk of disease-specific mortality for the most aﬄuent and the
most deprived patients had narrowed in all models, which can
be demonstrated by a reduction in all the models’ SIIs between
1-, 5-, and 12-year follow-up—for example, in the model that
was minimally adjusted by age and sex, the SII had reduced
from 1.1 (0.2, 1.9) at 1-year, to 0.7 (0.1, 1.2) at 5-years, to 0.7
(0.2, 1.2) at 12-years, whereas in the fully adjusted model the SII
had reduced from 0.2 (−0.5, 0.9) at 1-year, to 0.1 (−0.7, 1.0) at
5-years, and −0.1 (−0.5, 0.9) at 12-years. There was statistical
evidence of a difference in the risk of disease-specific mortality
at 5- and 12-years in the models adjusted by age, sex, tumor and
treatment factors which is determined by the patients in group
3 (intermediate aﬄuency) having 49% excess risk of disease-
specific mortality [HR = 1.49, (1.10, 2.03)] and 38% excess risk
of disease-specific mortality [HR = 1.38, (1.04, 1.85)] at 5- and
12-years, respectively, compared to those who were in the most
aﬄuent group. However, there was no evidence of an inequality
across the groups from the SIIs at 5- or 12-years [SII= 0.3, (−0.7,
1.4] and 0.3, (−0.6, 1.2, respectively).
DISCUSSION
This study demonstrates a clear gradient across Carstairs
quintiles for minimally adjusted overall, disease-specific and
net survival at 1-, 5-, and 12-years for patients with a
diagnosis of HNC made between the years of 1999 and 2001
from Scotland. Following full adjustment at 1-, 5-, and 12-
years, the inequality was no longer statistically significant
suggesting that the inequality in the survival of patients
with HNC can be explained by multiple patient, tumor and
treatment factors. As an additional analysis, we also investigated
the impact of individual co-variates on the inequality in
survival, but the inequality remained strong at all three time
points for all-cause mortality and disease-specific mortality
(Supplementary Tables 1, 2), suggesting that the inequality in
the survival of patients with HNC is not straightforward, and
many factors play a combined effect in the role of the explanation
of the inequality in HNC survival. The results for the net survival
(unadjusted) analysis demonstrated a clear gradient across the
Carstairs fifths at 1- and 5-years, but this gradient disappears
by 12-years, suggesting that some of the inequality in long-term
survival is partly attributable to background mortality, and since
this cohort has such long follow-up, influence from background
mortality is to be expected.
There are several limitations to this study. Firstly, SES was
measured using the area based Carstairs 2001 Index (9, 10), which
is derived from 2001 Census data involving the proportion of
male unemployment, those in social classes IV and V, lack of
car ownership, and overcrowding in a dwelling. Since this was
a clinical cohort study, further data on SES indexes including
education level and amount of income, was not collected as part
of this study. Carstairs 2001 Index may not accurately represent
rural and urban populations as it may be essential for people
in these areas to own a car, however as other indices such as
education level of income were not available for this analysis,
Carstairs 2001 scores were the bestmeasurement available for this
analysis.
A further limitation of this study is the use of disease-specific
survival which was classified from a patient having a primary
cause of death of a form of HNC on their death certificates.
Death certificates often contain several causes of death and so an
exact cause of patients’ death is not usually possible to determine,
therefore we advise that these results are interpreted with caution
due to the reliability of the reporting of cause of death from
death certificates. Due to this, we have included net survival
estimates alongside overall and disease-specific survival results
to give an additional representation of HNC-specific deaths. Net
survival determines the excess hazard of death from HNC, and
therefore the impact of background mortality in HNC survival
can be assessed. However, net survival cannot be computed
in Cox Proportional Hazard analyses to run adjustment for
additional confounders, and so all-cause and disease-specific
mortality models together with net survival estimates provide a
thorough insight into the burden of disease in HNC patients.
There has been an increase in the incidence of HPV-
associated HNC over the last 20 years (20–22), which mostly
involves cancers of the oropharynx. Around two-thirds of
oropharynx cancers may be explained by HPV (23), and
patients have substantially better prognoses than those with
non-HPV-driven tumors, suggesting that one limitation of this
study is the absence of HPV data (24, 25). These data were
collected between the years of 1999 and 2001, which was
before the discovery of the significant difference in survival
between HPV-positive and HPV-negative HNC tumors (26),
and thus HPV data was not collected as part of this study.
Smoking and alcohol consumption are the main risk factors
for non-oropharyngeal HNC tumors, and apart from tumors
of the oropharynx, most HNCs are HPV-negative (27, 28).
The marked improvement of in the survival of patients with
HPV-positive oropharyngeal tumors was not observed in this
study (data not shown), suggesting that these tumors are likely
to be HPV-negative and therefore mostly explained by the
high prevalence of smoking and alcohol consumption in this
cohort (27, 28). HPV status, smoking behavior and alcohol
consumption are three independent risk factors of survival
(29, 30), and therefore we believe that the majority of cancers
in this study are smoking and alcohol related and thus we
believe that our findings are relevant despite missing HPV
data.
Socioeconomic inequalities are present in HNC survival and
are observed between and within countries. There are global
inequalities in the incidence and mortality of HNC, and around
two thirds of cases and three-quarters of deaths occur in low- or
middle-income countries1. Paterson et al. (31) reported that the
initial differences in survival (up to 18 months from diagnosis)
may be explained by an advanced stage at diagnosis in the
patients who were most deprived, and once this effect was
eliminated, deprivation was no longer a predictor of patient
prognosis for those who survive beyond 18 months. Ellis et al.
1http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/
World-Cancer-Report-2014
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(32) confirmed that there was a gap in relative survival by
deprivation at both 1 and 5 years in favor of the patients
from socioeconomically advantaged areas and concluded that the
origins of the inequalities were unclear, although it was likely that
comorbidities and healthcare access were contributing toward
the differences.
This study adds to the understanding of the inequality in
survival for head and neck cancer patients. The SAHNC cohort
represented 77% of all HNC cases on the Scottish Cancer Registry
over a 2-year period and is therefore a good representation of
HNC cases in Scotland. In unadjusted models, a clear gradient
across Carstairs quintiles for overall, disease-specific and net
survival was observed at 1-, 5-, and 12-years for this cohort of
HNC patients. Following adjustment for multiple patient, tumor
and treatment factors the inequality was no longer present for
all-cause and disease-specificmortality. This study concludes that
explanations for the inequality in survival of patients with HNC
are not straightforward. Many factors, including various patient,
tumor and treatment factors, play a part in the inequality of
survival in patients with HNC.
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